×
Hero Background

Americas Cancer Biologic Therapy Companies

ID: MRFR/Pharma/0148-HCR
45 Pages
Rahul Gotadki
October 2025

Companies in the Americas specializing in cancer biological therapy contribute to oncology by developing and providing biologically derived therapies for cancer treatment. These therapies may include monoclonal antibodies, immunotherapies, and targeted therapies that harness the body's immune system to combat cancer cells, improving treatment outcomes.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Americas Cancer Biological Therapy Market Research Report- Forecast To 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Americas Cancer Biologic Therapy Market

Americas Cancer Biological Therapy Companies

 


Latest Americas Cancer Biological Therapy Companies Updates:


Dec 2023


Bristol-Myers SquibbReceived FDA approval for their Opdivo® (nivolumab) and Yervoy® (ipilimumab) combination therapy for first-line treatment of advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression.Partnered with academic institutions to explore the potential of their biologic therapies for treating additional cancer types and early-stage disease.


Roche Holding AG Announced positive Phase III data for their Tecentriq® (atezolizumab) in combination with chemotherapy for the treatment of advanced bladder cancer.Launched their Foundation® Medicine platform in Brazil, providing personalized genomic testing and treatment recommendations for cancer patients.


Merck & Co.Presented encouraging data at a major oncology conference on their Keytruda® (pembrolizumab) for the treatment of head and neck cancer.Collaborated with government agencies in Latin America to improve access to their cancer biologic therapies for underserved populations.


Eli Lilly and Company Received FDA approval for their Verzenio® (abemaciclib) as a first-line treatment for advanced HR-positive, HER2-negative breast cancer.Announced plans to expand their clinical trial portfolio in the Americas to include more diverse patient populations.


AbbVie Launched their Venclexta® (venetoclax) in combination with Rituximab for the treatment of chronic lymphocytic leukemia (CLL) in Argentina and Brazil.Partnered with patient advocacy groups to raise awareness about CLL and improve access to treatment options.


List of Americas Cancer Biological Therapy Key companies in the market



  • Hoffmann-La Roche AG,

  • GSK, Merck & Co.,

  • Novartis International AG, Inc.,

  • GlaxoSmithKline Plc,

  • Bristol-Myers Squibb,

  • Eli Lilly,

  • Amgen Inc.,

  • Spectrum Pharmaceuticals, Inc.,

  • Seattle Genetics, Inc.,

  • Celgene Corporation